Intelligence / Healthtech / New Clinical Trials / Biogen
Clinicaltrial registered22 Oct 2026
Biogen
22 Oct 2026: Trial registered · A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN). Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 22 Oct 2026
- Title
- A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN)
- Conditions
- Immunoglobulin A Nephropathy
- Phase
- Phase 2
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Reference
- NCT07889362
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Biogen
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for Biogen in our registers.
20 OctBiogen GmbHwon a public contract · HealthtechProcurement16 NovBiogentrial registered · HealthtechClinical21 OctBiogentrial registered · HealthtechClinical
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.